Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement-Reference-Cited by-同舟云学术

Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement

Published:2020-10-13 Issue:19 Volume:4 Page:4924-4928
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Carll Timothy¹^ORCID,Patel Anand²^ORCID,Derman Benjamin²^ORCID,Hyjek Elizabeth¹,Lager Angela¹^ORCID,Wanjari Pankhuri¹^ORCID,Segal Jeremy¹^ORCID,Odenike Olatoyosi²^ORCID,Fidai Shiraz³^ORCID,Arber Daniel¹^ORCID

Affiliation:

1. Department of Pathology, and

2. Department of Hematology/Oncology, University of Chicago, Chicago, IL; and

3. Department of Pathology and Laboratory Medicine, John H. Stroger Hospital of Cook County, Chicago, IL

Abstract

Key Points Myeloid/lymphoid neoplasms with eosinophilia are driven by aberrant tyrosine kinases in pluripotent cells and display variable phenotypes. FGFR-driven hematolymphoid neoplasms are targetable by TKI inhibitors such as ponatinib; studies of specific FGFR inhibitors are ongoing.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/19/4924/1761849/advancesadv2019001282.pdf

Reference26 articles.

1. STAR: ultrafast universal RNA-seq aligner;Dobin;Bioinformatics,2013

2. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403;Stock;Blood,2019

3. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification;Matutes;Blood,2011

4. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML);Larson;Leuk Lymphoma,2012

5. FGFR a promising druggable target in cancer: molecular biology and new drugs;Porta;Crit Rev Oncol Hematol,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes;Genetics in Medicine;2024-04

2. Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis;Cancers;2024-03-31

3. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-03-29

4. Hematological Neoplasms with Eosinophilia;Cancers;2024-01-12

5. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions and acute leukemias of mixed or ambiguous lineage;Atlas of Hematopathology with 100 Case Studies;2024